Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $24 price target.
June 15, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst reaffirms Buy rating on Coherus BioSciences (NASDAQ:CHRS) and keeps $24 price target.
The reiteration of the Buy rating and maintenance of the $24 price target by Truist Securities analyst Robyn Karnauskas indicates a positive outlook for Coherus BioSciences. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100